Beclabuvir hydrochloride is primarily used in the treatment of chronic hepatitis C virus (HCV) infections. It functions as an NS5A inhibitor, targeting a specific protein essential for viral replication. This compound is often included in combination therapies to enhance efficacy and reduce the risk of resistance. By inhibiting viral replication, it helps lower the viral load in patients, contributing to improved liver function and overall health outcomes. Its application is particularly significant in patients with genotype 1 HCV, where it has shown promising results in achieving sustained virologic response (SVR). The use of this compound has been a critical advancement in the development of direct-acting antiviral (DAA) treatments, offering a more effective and tolerable option compared to older interferon-based therapies.